SNP-630-MS

**SNP-630-MS** is an orally administered, synthetic small-molecule metabolite mixture derived from the MASH candidate SNP-630 and developed by Sinew Pharma. It consists of two active metabolites of SNP-630 and has also been reported under the clinical-development code SNP-612. In preclinical MASH models and a small Phase 2 clinical study, it reduced serum alanine aminotransferase, hepatic triglyceride accumulation, inflammatory chemokine expression, and fibrosis-associated biomarkers. Its proposed mechanism includes suppression of cytochrome P450 2E1 expression, reducing reactive oxygen species generation, together with inhibition of hepatic de novo lipogenesis and downstream inflammatory and profibrotic signaling.